A randomized, double-blind, active comparator-controlled, parallel-group study conducted under in-house blinding conditions, to examine the safety and tolerability of IV MK-0517 [fosaprepitant] for the prevention of postoperative nausea and vomiting (PONV)

Trial Profile

A randomized, double-blind, active comparator-controlled, parallel-group study conducted under in-house blinding conditions, to examine the safety and tolerability of IV MK-0517 [fosaprepitant] for the prevention of postoperative nausea and vomiting (PONV)

Completed
Phase of Trial: Phase III

Latest Information Update: 05 Nov 2014

At a glance

  • Drugs Fosaprepitant (Primary) ; Ondansetron
  • Indications Postoperative nausea and vomiting
  • Focus Adverse reactions
  • Acronyms COMPLETED
  • Sponsors Merck
  • Most Recent Events

    • 05 Nov 2010 Trial location (USA) identified as reported by ClinicalTrials.gov.
    • 22 Jan 2009 Actual end date (Feb 2006) added as reported by ClinicalTrials.gov.
    • 22 Jan 2009 Actual patient number (216) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top